The Human Reproductive Technologies Market study analyzes and forecasts the market size across 6 regions and 24 countries for diverse segments- By Infertility Treatment (Drugs (Follitropin Alfa, Follitropin Beta, Menotropins), Devices (Sperm Separation Devices, Sperm Analyzer Systems, Ovum Aspiration Pumps, Micromanipulator Systems)), By Contraceptive (Drugs (Oral, Topical, Contraceptive), Devices (Condoms, IUD, Cervical Caps, Diaphragms)), By Gender (Male, Female).
In 2024, the market for human reproductive technologies continues to advance rapidly, driven by increasing demand for assisted reproductive techniques and advancements in reproductive medicine. Human reproductive technologies encompass a wide range of procedures and treatments aimed at overcoming infertility and assisting couples in achieving pregnancy. Techniques such as in vitro fertilization (IVF), intracytoplasmic sperm injection (ICSI), and preimplantation genetic testing (PGT) have become standard procedures in fertility clinics worldwide, offering hope to millions of individuals struggling with infertility. Moreover, innovations in reproductive technologies, including time-lapse embryo imaging, mitochondrial replacement therapy, and artificial gametes, are expanding treatment options and improving success rates for patients undergoing assisted reproduction. Additionally, the growing acceptance of third-party reproduction, including egg donation and gestational surrogacy, is further driving market growth and providing alternative pathways to parenthood. With fertility rates declining globally and the increasing prevalence of age-related infertility, the human reproductive technologies market is poised for continued expansion and innovation to meet the evolving needs of individuals and couples seeking to build their families.
A significant trend in the market for human reproductive technologies is the continuous advancements in assisted reproductive technologies (ART). With ongoing research and technological innovations, ART procedures such as in vitro fertilization (IVF), intracytoplasmic sperm injection (ICSI), and preimplantation genetic testing (PGT) are becoming more sophisticated, efficient, and accessible. Emerging techniques such as mitochondrial replacement therapy (MRT) and ovarian tissue cryopreservation are also expanding the scope of reproductive options available to individuals and couples facing infertility challenges. This trend reflects a growing demand for cutting-edge reproductive technologies that offer improved success rates, reduced risks, and expanded treatment options for infertility patients worldwide.
The primary driver propelling the market for human reproductive technologies is the increasing incidence of infertility and delayed childbearing. Factors such as lifestyle changes, environmental factors, advancing maternal age, and rising prevalence of conditions such as polycystic ovary syndrome (PCOS) contribute to a growing number of individuals and couples experiencing difficulties conceiving naturally. As a result, there is rising demand for fertility treatments and reproductive technologies to overcome infertility challenges and fulfill the desire for parenthood. This demographic trend drives investment in research, development, and adoption of human reproductive technologies to address the unmet needs of individuals and couples seeking to build their families.
An attractive opportunity within the market for human reproductive technologies is the expansion of access to fertility preservation and LGBTQ+ family building services. As awareness of fertility preservation options grows, there is increasing demand for services such as egg freezing, sperm banking, and embryo cryopreservation among individuals and couples seeking to preserve their fertility for future family planning. Additionally, with advances in reproductive medicine and social acceptance of diverse family structures, there is a growing demand for assisted reproduction services for LGBTQ+ individuals and couples who wish to conceive and build their families through donor sperm, donor eggs, surrogacy, or other ART procedures. This presents an opportunity for fertility clinics, reproductive endocrinologists, and ART providers to expand their offerings, tailor services to diverse patient populations, and improve access to comprehensive reproductive care for all individuals and families.
In the Human Reproductive Technologies Market, the segment experiencing the fastest growth is Infertility Treatment Devices. These devices, including sperm separation devices, sperm analyzer systems, ovum aspiration pumps, and micromanipulator systems, play a crucial role in assisted reproductive technologies (ART) used to address infertility issues in both men and women. As the prevalence of infertility continues to rise globally, there is increasing demand for advanced and effective infertility treatment devices to aid in procedures such as in vitro fertilization (IVF), intrauterine insemination (IUI), and intracytoplasmic sperm injection (ICSI). Moreover, technological advancements in infertility treatment devices, such as improved precision, efficiency, and automation, are driving their adoption among fertility clinics and healthcare providers. With growing awareness about infertility treatment options and increasing acceptance of ART procedures, the demand for infertility treatment devices is expected to grow rapidly. Consequently, the infertility treatment devices segment is poised for significant growth in the human reproductive technologies market.
The market research study provides in-depth insights into leading companies including the SWOT analyses, product profile, financial details, and recent developments acrossAbbVie Inc, Bayer AG, CooperSurgical Inc, Ferring B.V., Genea Ltd, Ivftech, Merck KGaA, Teva Pharmaceutical Industries
By Infertility Treatment
Drugs
-Follitropin Alfa
-Follitropin Beta
-Menotropins
-Others
Devices
-Sperm Separation Devices
-Sperm Analyzer Systems
-Ovum Aspiration Pumps
-Micromanipulator Systems
-Others
By Contraceptive
Drugs
-Oral
-Topical
-Contraceptive
Devices
-Condoms
-IUD
-Cervical Caps
-Diaphragms
-Others
By Gender
Male
Female
Geographical Analysis
North America (United States, Canada, Mexico)
Europe (Germany, France, United Kingdom, Spain, Italy, Rest of Europe)
Asia Pacific (China, India, Japan, South Korea, Rest of Asia Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East and Africa (Saudi Arabia, UAE, Rest of Middle East, South Africa, Egypt, Rest of Africa)
AbbVie Inc
Bayer AG
CooperSurgical Inc
Ferring B.V.
Genea Ltd
Ivftech
Merck KGaA
Teva Pharmaceutical Industries
• Deepen your industry insights and navigate uncertainties for strategy formulation, CAPEX, and Operational decisions
• Gain access to detailed insights on the Human Reproductive Technologies Market, encompassing current market size, growth trends, and forecasts till 2030.
• Access detailed competitor analysis, enabling competitive advantage through a thorough understanding of market players, strategies, and potential differentiation opportunities
• Stay ahead of the curve with insights on technological advancements, innovations, and upcoming trends
• Identify lucrative investment avenues and expansion opportunities within the Human Reproductive Technologies Market industry, guided by robust, data-backed analysis.
• Understand regional and global markets through country-wise analysis, regional market potential, regulatory nuances, and dynamics
• Execute strategies with confidence and speed through information, analytics, and insights on the industry value chain
• Corporate leaders, strategists, financial experts, shareholders, asset managers, and governmental representatives can make long-term planning scenarios and build an integrated and timely understanding of market dynamics
• Benefit from tailored solutions and expert consultation based on report insights, providing personalized strategies aligned with specific business needs.
TABLE OF CONTENTS
1 Introduction to 2024 Human Reproductive Technologies Market
1.1 Market Overview
1.2 Quick Facts
1.3 Scope/Objective of the Study
1.4 Market Definition
1.5 Countries and Regions Covered
1.6 Units, Currency, and Conversions
1.7 Industry Value Chain
2 Research Methodology
2.1 Market Size Estimation
2.2 Sources and Research Methodology
2.3 Data Triangulation
2.4 Assumptions and Limitations
3 Executive Summary
3.1 Global Human Reproductive Technologies Market Size Outlook, $ Million, 2021 to 2030
3.2 Human Reproductive Technologies Market Outlook by Type, $ Million, 2021 to 2030
3.3 Human Reproductive Technologies Market Outlook by Product, $ Million, 2021 to 2030
3.4 Human Reproductive Technologies Market Outlook by Application, $ Million, 2021 to 2030
3.5 Human Reproductive Technologies Market Outlook by Key Countries, $ Million, 2021 to 2030
4 Market Dynamics
4.1 Key Driving Forces of Human Reproductive Technologies Industry
4.2 Key Market Trends in Human Reproductive Technologies Industry
4.3 Potential Opportunities in Human Reproductive Technologies Industry
4.4 Key Challenges in Human Reproductive Technologies Industry
5 Market Factor Analysis
5.1 Value Chain Analysis
5.2 Competitive Landscape
5.2.1 Global Human Reproductive Technologies Market Share by Company (%), 2023
5.2.2 Product Offerings by Company
5.3 Porter’s Five Forces Analysis
5.4 Pricing Analysis and Outlook
6 Growth Outlook Across Scenarios
6.1 Growth Analysis-Case Scenario Definitions
6.2 Low Growth Scenario Forecasts
6.3 Reference Growth Scenario Forecasts
6.4 High Growth Scenario Forecasts
7 Global Human Reproductive Technologies Market Outlook by Segments
7.1 Human Reproductive Technologies Market Outlook by Segments, $ Million, 2021- 2030
By Infertility Treatment
Drugs
-Follitropin Alfa
-Follitropin Beta
-Menotropins
-Others
Devices
-Sperm Separation Devices
-Sperm Analyzer Systems
-Ovum Aspiration Pumps
-Micromanipulator Systems
-Others
By Contraceptive
Drugs
-Oral
-Topical
-Contraceptive
Devices
-Condoms
-IUD
-Cervical Caps
-Diaphragms
-Others
By Gender
Male
Female
8 North America Human Reproductive Technologies Market Analysis and Outlook To 2030
8.1 Introduction to North America Human Reproductive Technologies Markets in 2024
8.2 North America Human Reproductive Technologies Market Size Outlook by Country, 2021-2030
8.2.1 United States
8.2.2 Canada
8.2.3 Mexico
8.3 North America Human Reproductive Technologies Market size Outlook by Segments, 2021-2030
By Infertility Treatment
Drugs
-Follitropin Alfa
-Follitropin Beta
-Menotropins
-Others
Devices
-Sperm Separation Devices
-Sperm Analyzer Systems
-Ovum Aspiration Pumps
-Micromanipulator Systems
-Others
By Contraceptive
Drugs
-Oral
-Topical
-Contraceptive
Devices
-Condoms
-IUD
-Cervical Caps
-Diaphragms
-Others
By Gender
Male
Female
9 Europe Human Reproductive Technologies Market Analysis and Outlook To 2030
9.1 Introduction to Europe Human Reproductive Technologies Markets in 2024
9.2 Europe Human Reproductive Technologies Market Size Outlook by Country, 2021-2030
9.2.1 Germany
9.2.2 France
9.2.3 Spain
9.2.4 United Kingdom
9.2.4 Italy
9.2.5 Russia
9.2.6 Norway
9.2.7 Rest of Europe
9.3 Europe Human Reproductive Technologies Market Size Outlook by Segments, 2021-2030
By Infertility Treatment
Drugs
-Follitropin Alfa
-Follitropin Beta
-Menotropins
-Others
Devices
-Sperm Separation Devices
-Sperm Analyzer Systems
-Ovum Aspiration Pumps
-Micromanipulator Systems
-Others
By Contraceptive
Drugs
-Oral
-Topical
-Contraceptive
Devices
-Condoms
-IUD
-Cervical Caps
-Diaphragms
-Others
By Gender
Male
Female
10 Asia Pacific Human Reproductive Technologies Market Analysis and Outlook To 2030
10.1 Introduction to Asia Pacific Human Reproductive Technologies Markets in 2024
10.2 Asia Pacific Human Reproductive Technologies Market Size Outlook by Country, 2021-2030
10.2.1 China
10.2.2 India
10.2.3 Japan
10.2.4 South Korea
10.2.5 Indonesia
10.2.6 Malaysia
10.2.7 Australia
10.2.8 Rest of Asia Pacific
10.3 Asia Pacific Human Reproductive Technologies Market size Outlook by Segments, 2021-2030
By Infertility Treatment
Drugs
-Follitropin Alfa
-Follitropin Beta
-Menotropins
-Others
Devices
-Sperm Separation Devices
-Sperm Analyzer Systems
-Ovum Aspiration Pumps
-Micromanipulator Systems
-Others
By Contraceptive
Drugs
-Oral
-Topical
-Contraceptive
Devices
-Condoms
-IUD
-Cervical Caps
-Diaphragms
-Others
By Gender
Male
Female
11 South America Human Reproductive Technologies Market Analysis and Outlook To 2030
11.1 Introduction to South America Human Reproductive Technologies Markets in 2024
11.2 South America Human Reproductive Technologies Market Size Outlook by Country, 2021-2030
11.2.1 Brazil
11.2.2 Argentina
11.2.3 Rest of South America
11.3 South America Human Reproductive Technologies Market size Outlook by Segments, 2021-2030
By Infertility Treatment
Drugs
-Follitropin Alfa
-Follitropin Beta
-Menotropins
-Others
Devices
-Sperm Separation Devices
-Sperm Analyzer Systems
-Ovum Aspiration Pumps
-Micromanipulator Systems
-Others
By Contraceptive
Drugs
-Oral
-Topical
-Contraceptive
Devices
-Condoms
-IUD
-Cervical Caps
-Diaphragms
-Others
By Gender
Male
Female
12 Middle East and Africa Human Reproductive Technologies Market Analysis and Outlook To 2030
12.1 Introduction to Middle East and Africa Human Reproductive Technologies Markets in 2024
12.2 Middle East and Africa Human Reproductive Technologies Market Size Outlook by Country, 2021-2030
12.2.1 Saudi Arabia
12.2.2 UAE
12.2.3 Oman
12.2.4 Rest of Middle East
12.2.5 Egypt
12.2.6 Nigeria
12.2.7 South Africa
12.2.8 Rest of Africa
12.3 Middle East and Africa Human Reproductive Technologies Market size Outlook by Segments, 2021-2030
By Infertility Treatment
Drugs
-Follitropin Alfa
-Follitropin Beta
-Menotropins
-Others
Devices
-Sperm Separation Devices
-Sperm Analyzer Systems
-Ovum Aspiration Pumps
-Micromanipulator Systems
-Others
By Contraceptive
Drugs
-Oral
-Topical
-Contraceptive
Devices
-Condoms
-IUD
-Cervical Caps
-Diaphragms
-Others
By Gender
Male
Female
13 Company Profiles
13.1 Company Snapshot
13.2 SWOT Profiles
13.3 Products and Services
13.4 Recent Developments
13.5 Financial Profile
List of Companies
AbbVie Inc
Bayer AG
CooperSurgical Inc
Ferring B.V.
Genea Ltd
Ivftech
Merck KGaA
Teva Pharmaceutical Industries
14 Appendix
14.1 Customization Offerings
14.2 Subscription Services
14.3 Related Reports
14.4 Publisher Expertise
By Infertility Treatment
Drugs
-Follitropin Alfa
-Follitropin Beta
-Menotropins
-Others
Devices
-Sperm Separation Devices
-Sperm Analyzer Systems
-Ovum Aspiration Pumps
-Micromanipulator Systems
-Others
By Contraceptive
Drugs
-Oral
-Topical
-Contraceptive
Devices
-Condoms
-IUD
-Cervical Caps
-Diaphragms
-Others
By Gender
Male
Female
Countries Analyzed
North America (United States, Canada, Mexico)
Europe (Germany, France, United Kingdom, Spain, Italy, Rest of Europe)
Asia Pacific (China, India, Japan, South Korea, Rest of Asia Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East and Africa (Saudi Arabia, UAE, Rest of Middle East, South Africa, Egypt, Rest of Africa)
The global Human Reproductive Technologies Market is one of the lucrative growth markets, poised to register a 4.8% growth (CAGR) between 2024 and 2030.
Emerging Markets across Asia Pacific, Europe, and Americas present robust growth prospects.
AbbVie Inc, Bayer AG, CooperSurgical Inc, Ferring B.V., Genea Ltd, Ivftech, Merck KGaA, Teva Pharmaceutical Industries
Base Year- 2023; Estimated Year- 2024; Historic Period- 2018-2023; Forecast period- 2024 to 2030; Currency: USD; Volume